JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.74
+1.39%Margins
Gross margin
100.0%
EBITDA margin
-419.5%
EBIT margin
-598.1%
Net margin
-427.5%
FCF margin
-174.7%
-11.1%
Return on equity
-10.2%
Return on assets
-15.1%
Return on invested capital
0.02x
Asset turnover
-$41.3M
Cash from operations
$16
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026